摘要
文章通过对我国医药行业所处的大环境和现状进行分析,从医疗机构、患者、政府和医药企业这四方利益共同体着手,深入剖析医药行业发展的疼痛点,针对性地提出我国应采取的营商环境优化措施。从当前医药技术和产品的创新结果入手佐证创新的可行性,希望能对我国医药行业的创新发展和营商环境优化提供一定的参考。
Through the analysis of the environment and current situation of China's pharmaceutical industry,from the medical institutions,patients,the government and pharmaceutical enterprises,the community of these four common interests,the paper analyzes the pain points of the development of the pharmaceutical industry,and targeted measures should be taken to optimize the business environment in China.From the current pharmaceutical technology and product innovation results to prove the feasibility of innovation,it hopes to provide a certain reference for the innovation and development of China's pharmaceutical industry and optimizing the business environment.
作者
王曼
WANG Man(School of Economics and Management,Yangtze University,Jingzhou 434020,China)
出处
《商业观察》
2024年第3期117-120,共4页
BUSINESS OBSERVATION
关键词
企业创新
集中采购
医保改革
enterprise innovation
centralized procurement
medical insurance reform
